Therapeutic-dose anticoagulation has contributed to a decrease in the likelihood of organ support or death among noncritically ill hospitalized patients with COVID-19. Such experience shows how quick and rigorous approaches, when aligned, can promptly translate evidence into practice, suggests a study.
“The COVID-19 anticoagulation experience illustrates that rapid, coordinated, and methodologically rigorous approaches are not mutually exclusive but must be strategically aligned to generate timely, actionable evidence,” the investigators said.
“Although therapeutic-dose anticoagulation was associated with improved outcomes in noncritically ill hospitalized patients, the broader contribution of this work lies in illustrating how evidence was generated and interpreted under uncertainty,” they added.
The investigators examined how evidence on anticoagulation in COVID-19 was generated and translated into clinical guidance. They searched for randomized controlled trials (RCTs) comparing therapeutic- vs nontherapeutic-dose anticoagulation in noncritically ill patients hospitalized for COVID-19, summarizing trial characteristics, evidence accumulation, and associated guideline recommendations over time.
Using mixed-effects logistic regression, an individual participant data meta-analysis (IPDMA) was conducted to estimate summary treatment effects. The investigators noted the evolution of evidence from an early coordinated platform RCT (preprint May 2021) to subsequent RCTs published between June 2021 and July 2023.
Based on exploratory counterfactual sequential IPDMA, a statistically significant pooled treatment effect on organ support or death was observed in May 2021, nearly 13 months after the first patient enrolment (adjusted odds ratio [aOR], 0.73, 95 percent confidence interval [CI], 0.58‒0.91; six RCTs, n=3,944). [J Am Coll Cardiol 2026;88:437-450]
Subsequently, guideline recommendations shifted from uniform endorsement of prophylactic-dose anticoagulation in 2020 to those supporting therapeutic-dose anticoagulation in 2022, with variations in certainty across guidelines. The investigators collected individual participant data after completion of data transfer in April 2024 and included seven RCTs involving a total of 6,362 patients.
Therapeutic-dose anticoagulation resulted in lower chances of organ support or death (12.9 percent vs 16.2 percent; aOR, 0.81, 95 percent CI, 0.67‒0.97) in noncritically ill patients with COVID-19. Notably, major bleeding hardly occurred (0.8 percent vs 0.5 percent).
“Strengthening coordinated research networks, platform trial infrastructures, prioritized funding, and near-real-time cross-trial synthesis may improve the timeliness and reliability of evidence generation and guideline responsiveness during future public health emergencies,” the investigators said.
Guidelines evolution
During the COVID-19 pandemic (between 2020 and 2022), clinicians, investigators, and guideline committees had to make decisions amidst rapidly evolving and incomplete evidence.
During the initial phase of the pandemic, recommendations relied on observational data and pathophysiologic rationale, with concerns regarding thrombotic risk but limited randomized evidence. Moreover, initial guidance favoured prophylactic-dose anticoagulation with very low certainty. [CMAJ 2020;192:E1156-E1161; Eur J Haematol 2021;106:165-174; Blood Adv 2021;5:872-888]
The first adequately powered randomized data only became available in mid-2021, indicating beneficial effects from therapeutic-dose anticoagulation in noncritically ill hospitalized patients. However, uncertainties persisted regarding generalizability, bleeding risk, and evolving standard of care, the investigators said. [Chest 2022;161:1446-1448; Chest 2022;161:1448-1451]
Because of this, guideline panels had to make decisions based on emerging signals while awaiting confirmatory data, giving rise to variations in the timing and strength of recommendations. This then also led to differences in the adoption of therapeutic-dose strategies across organizations. [Chest 2022;162:213-225; J Thromb Haemost 2022;20:2214-2225; Blood Adv 2022;6:4975-4982]
“These patterns reflect the realities of decision-making under uncertainty rather than deficiencies in interpretation,” the investigators said. “The cumulative evidence, now reinforced by this IPDMA, supports therapeutic-dose anticoagulation in appropriately selected noncritically ill patients, while underscoring the importance of individualized decision-making as baseline risk continues to decline.”